| 2023-10 |
Discovery of novel AXL and MER inhibitors as potential anticancer and immune modulator drugs |
Annals of Oncology. 2023 Oct;34(Suppl. 2):S214. |
|
| 2019-10 |
The molecular mechanisms of EpCAM in regulating tumor progression and development of anti-EpCAM antibodies for colon cancer diagnosis and therapy |
Annals of Oncology. 2019 Oct;30(Suppl. 5):786. |
 |
| 2019-10 |
Discovery of clinical candidate DBPR112, a furanopyrimidine-based epidermal growth factor receptor inhibitor for the treatment of non-small cell lung cancer |
Annals of Oncology. 2019 Oct;30(Suppl. 5):789. |
|
| 2018-07 |
Clinical candidate DBPR112: A novel epidermal growth factor receptor inhibitor as a promising treatment for non-small cell lung cancer |
Cancer Research. 2018 Jul;78(13, Suppl.):Meeting Abstract 4789. |
|
| 2018-07 |
Blockage of EGFR signaling repurposes tumor metabolism through suppression of glycolysis and Kreb cycle in head and neck cancer |
Cancer Research. 2018 Jul;78(13, Suppl.):Meeting Abstract 3944. |
|
| 2018-01 |
Discovery and development of DBPR112 as a clinical candidate: A novel EGFR inhibitor for non-small cell lung cancer |
Cancer Science. 2018 Jan;109(Suppl. 1):739. |
|
| 2017-04 |
Toward the total syntheses of natural products containing trans-decalin skeleton from masked o-benzoquinone |
Abstracts of Papers of the American Chemical Society. 2017 Apr;253:Meeting Abstract 516. |
|
| 2017-04 |
Discovery of BPR1K871-a quinazoline based multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation |
Abstracts of Papers of the American Chemical Society. 2017 Apr;253:Meeting Abstract 482. |
|
| 2017-04 |
One-pot tandem oxidative dearomatization/ 4+3 cycloaddition: Masked o-benzoquinone with diaza-oxyallyl cation |
Abstracts of Papers of the American Chemical Society. 2017 Apr;253:Meeting Abstract 185. |
|
| 2015-08 |
BPR2P001S0, a Coumarin derivative, induced cell cycle arrest in A549 through inhibiting PDPK1 activity |
Cancer Research. 2015 Aug;75:Abstract number 1754. |
|
| 2015-08 |
Optimization of furanopyrimidine-based kinase inhibitors: Identification of a BTK kinase inhibitor for the treatment of B cell lymphoma |
Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 180. |
|
| 2015-08 |
Discovery of 2,4-diaminopyrimidines bearing a unique pharmacophore as anaplastic lymphoma kinase inhibitors |
Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 182. |
|
| 2015-08 |
Optimization of quinazoline-based kinase inhibitors: Identification of a dual FLT3/AURKA kinase inhibitor for the treatment of acute myeloid leukemia |
Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 490. |
|
| 2014-11 |
Discovery of multiple kinases inhibitors, DBPR114, as the novel anti-cancer agent |
European Journal of Cancer. 2014 Nov;50(Suppl. 6):92-93. |
|
| 2014-11 |
CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors |
European Journal of Cancer. 2014 Nov;50(Suppl. 6):19-20. |
|
| 2014-10 |
Optimization of 5,6-fused pyrimidine-based kinase inhibitors by computer-aided drug design for the treatment of AML |
Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 2530. |
|
| 2014-10 |
Novel irreversible EGFR tyrosine kinase inhibitor, DBPR112, as a therapeutic candidate for lung adenocarcinoma |
Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 1756. |
|
| 2014-03 |
Efficient virtual screening using ligand efficiency based approach |
Abstracts of Papers - American Chemical Society. 2014 Mar;247:Article number 55-MEDI. |
|
| 2014-03 |
DBPR112, a potent and selective EGFR kinase inhibitor in preclinical study |
Abstracts of Papers - American Chemical Society. 2014 Mar;247:Article number 315-MEDI. |
|
| 2013-11 |
Peptide-mediated liposomal doxorubicin enhances drug delivery efficiency and therapeutic efficacy in lung cancer animal models |
Journal of Thoracic Oncology. 2013 Nov;8(Suppl. 2):S779. |
|
| 2013-11 |
A development drug candidate targeting EGFR kinase for lung cancer: DBPR112 |
Journal of Thoracic Oncology. 2013 Nov;8(Suppl. 2):S779-S780. |
|
| 2013-04-07 |
BPR000K, a novel Aurora kinase inhibitor |
Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 300-MEDI. |
|
| 2013-04-07 |
Kinase-focused library: Design and synthesis of pyrimidines derivatives bearing amino substituents using high throughput parallel synthesis |
Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 298-MEDI |
|
| 2013-04-07 |
3D-QSAR assisted drug design: Identification of a potent quinazoline based Aurora kinase inhibitor |
Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 87-MEDI. |
|
| 2013-04-07 |
Development drug candidate targeting EGFR kinase: DBPR112 |
Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 299-MEDI. |
|
